(0.08%) 5 250.50 points
(0.03%) 39 654 points
(0.15%) 18 283 points
(0.20%) $78.42
(1.38%) $2.28
(-0.94%) $2 352.70
(-0.58%) $28.34
(0.10%) $1 008.20
(-0.05%) $0.928
(0.14%) $10.85
(0.01%) $0.799
(-0.97%) $91.77
@ $1.749
Issued: 9 Feb 2024 @ 10:59
Return: 76.66%
Previous signal: Feb 8 - 15:16
Previous signal:
Return: 5.05 %
Live Chart Being Loaded With Signals
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients...
Stats | |
---|---|
Today's Volume | 31 985.00 |
Average Volume | 1.10M |
Market Cap | 81.23M |
EPS | $0 ( 2024-04-09 ) |
Next earnings date | ( $-0.250 ) 2024-06-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.970 |
ATR14 | $0.0160 (0.52%) |
Volume Correlation
Lava Therapeutics B.V. Correlation
10 Most Positive Correlations | |
---|---|
CGO | 0.923 |
TRVI | 0.922 |
NODK | 0.915 |
NXGN | 0.915 |
PCAR | 0.914 |
SHLD | 0.913 |
GRID | 0.912 |
RNA | 0.91 |
EBSB | 0.91 |
PLMR | 0.908 |
10 Most Negative Correlations | |
---|---|
UONE | -0.924 |
VORB | -0.918 |
BRQS | -0.915 |
UONEK | -0.913 |
TEDU | -0.907 |
QNRX | -0.905 |
TCPC | -0.895 |
PEAR | -0.895 |
SSP | -0.891 |
IRDM | -0.89 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Lava Therapeutics B.V. Correlation - Currency/Commodity
Lava Therapeutics B.V. Financials
Annual | 2023 |
Revenue: | $6.77M |
Gross Profit: | $3.29M (48.56 %) |
EPS: | $-1.570 |
FY | 2023 |
Revenue: | $6.77M |
Gross Profit: | $3.29M (48.56 %) |
EPS: | $-1.570 |
FY | 2022 |
Revenue: | $19.39M |
Gross Profit: | $19.39M (100.00 %) |
EPS: | $-1.230 |
FY | 2021 |
Revenue: | $5.00M |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-2.30 |
Financial Reports:
No articles found.
Lava Therapeutics B.V.
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators